E&G Advisors’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.11M | Buy |
1,773
+115
| +7% | +$118K | 0.41% | 45 |
|
|
2026
Q1 | $1.51M | Buy |
1,658
+18
| +1% | +$18.2K | 0.34% | 62 |
|
|
2025
Q4 | $1.75M | Sell |
1,640
-359
| -18% | -$343K | 0.39% | 47 |
|
|
2025
Q3 | $1.52M | Sell |
1,999
-32
| -2% | -$23.8K | 0.35% | 55 |
|
|
2025
Q2 | $1.58M | Hold |
2,031
| – | – | 0.41% | 47 |
|
|
2025
Q1 | $1.67M | Sell |
2,031
-300
| -13% | -$250K | 0.47% | 44 |
|
|
2024
Q4 | $1.79M | Sell |
2,331
-400
| -15% | -$331K | 0.49% | 35 |
|
|
2024
Q3 | $2.41M | Buy |
2,731
+180
| +7% | +$162K | 0.67% | 29 |
|
|
2024
Q2 | $2.3M | Hold |
2,551
| – | – | 0.68% | 29 |
|
|
2024
Q1 | $1.98M | Buy |
2,551
+1
| +0% | +$712 | 0.62% | 31 |
|
|
2023
Q4 | $1.49M | Buy |
2,550
+20
| +0.8% | +$11.7K | 0.53% | 40 |
|
|
2023
Q3 | $1.36M | Sell |
2,530
-200
| -7% | -$103K | 0.5% | 50 |
|
|
2023
Q2 | $1.28M | Hold |
2,730
| – | – | 0.45% | 57 |
|
|
2023
Q1 | $938K | Buy |
2,730
+30
| +1% | +$10.1K | 0.35% | 68 |
|
|
2022
Q4 | $988K | Hold |
2,700
| – | – | 0.37% | 65 |
|
|
2022
Q3 | $873K | Hold |
2,700
| – | – | 0.32% | 73 |
|
|
2022
Q2 | $875K | Hold |
2,700
| – | – | 0.3% | 77 |
|
|
2022
Q1 | $773K | Hold |
2,700
| – | – | 0.21% | 90 |
|
|
2021
Q4 | $746K | Hold |
2,700
| – | – | 0.19% | 105 |
|
|
2021
Q3 | $624K | Buy |
+2,700
| New | +$666K | 0.17% | 110 |
|
|
2021
Q2 | – | Sell |
-2,700
| Closed | -$542K | – | 114 |
|
|
2021
Q1 | $504K | Sell |
2,700
-600
| -18% | -$117K | 0.15% | 122 |
|
|
2020
Q4 | $557K | Buy |
3,300
+200
| +6% | +$29.9K | 0.17% | 110 |
|
|
2020
Q3 | $459K | Hold |
3,100
| – | – | 0.16% | 109 |
|
|
2020
Q2 | $509K | Hold |
3,100
| – | – | 0.2% | 96 |
|
|
2020
Q1 | $430K | Hold |
3,100
| – | – | 0.21% | 94 |
|
|
2019
Q4 | $407K | Sell |
3,100
-400
| -11% | -$46.4K | 0.15% | 133 |
|
|
2019
Q3 | $391K | Hold |
3,500
| – | – | 0.16% | 128 |
|
|
2019
Q2 | $388K | Hold |
3,500
| – | – | 0.17% | 125 |
|
|
2019
Q1 | $454K | Hold |
3,500
| – | – | 0.2% | 114 |
|
|
2018
Q4 | $405K | Buy |
3,500
+800
| +30% | +$89.4K | 0.18% | 135 |
|
|
2018
Q3 | $290K | Sell |
2,700
-2,200
| -45% | -$220K | 0.11% | 172 |
|
|
2018
Q2 | $418K | Buy |
4,900
+500
| +11% | +$41.1K | 0.17% | 133 |
|
|
2018
Q1 | $340K | Hold |
4,400
| – | – | 0.15% | 137 |
|
|
2017
Q4 | $372K | Buy |
+4,400
| New | +$374K | 0.16% | 137 |
|
Other funds holding LLY
SC
ONB
GIM
E&G Advisors's LLY Position: Q2 2026 in Review
E&G Advisors increased its Eli Lilly (LLY) stake by 6.9% in Q2 2026, buying an estimated $118K and bringing the position to 1,773 shares worth $2.11M. The position accounts for 0.41% of the portfolio, ranked #45.
E&G Advisors first reported a position in LLY in Q4 2017 and has held it in 34 quarters since. The position peaked at $2.41M in Q3 2024. 1,558 funds tracked by Wall St. Rank hold LLY as of Q2 2026.
- E&G Advisors held 1,773 shares of Eli Lilly worth $2.11M as of Q2 2026.
- E&G Advisors bought 115 Eli Lilly shares in Q2 2026, an estimated $118K.
- Eli Lilly made up 0.41% of E&G Advisors's portfolio in Q2 2026, its #45 holding.
- E&G Advisors first reported a position in Eli Lilly in Q4 2017 and has held it in 34 quarters since.
- E&G Advisors's Eli Lilly position peaked at $2.41M in Q3 2024.
- 1,558 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.
Based on E&G Advisors's 13F filing for Q2 2026, filed 23 Jul 2026.